Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiviral Therapy for Immune Tolerant Chronic Hepatitis B
NCT05382351Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tenofovir + amibufenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Inhibition rate of HBV-DNA at 96 weeks. Status: unknown.
02
Drugs
tenofovir + amibufenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05382351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382351.